Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 1/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.50 |
| ▸ | HTR2B | P41595 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.50 |
| ▸ | MMP2 | P08253 | 2/20 | 0.50 |
| ▸ | MMP9 | P14780 | 2/20 | 0.50 |
| ▸ | MMP8 | P22894 | 2/20 | 0.50 |
| ▸ | MMP13 | P45452 | 2/20 | 0.50 |
| ▸ | COMT | P21964 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16620020 | 0.92 | ALB (0.61) | ALBKDM4EALDH1A1HPGDNPC1 | |
| SCHEMBL16630755 | 0.84 | ALB (1.00) | ALBKDM4EHTR2BALDH1A1HPGD | |
| SCHEMBL16630759 | 0.78 | ALB (0.78) | ALBCHEK2MMP2MMP9MMP8 | |
| SCHEMBL16630761 | 0.77 | ALB (0.86) | ALBCHEK2MMP2MMP9MMP8 | |
| SCHEMBL20707604 | 0.77 | ALB (0.70) | ALBCHEK2POLBMAPTLMNA | |
| SCHEMBL16619621 | 0.76 | HTR2B (0.60) | KDM4EHTR2BALDH1A1HPGDNPC1 | |
| SCHEMBL5641199 | 0.73 | CHEK2 (0.75) | HTR2BCHEK2 | |
| SCHEMBL30444625 | 0.72 | FAAH (0.60) | KDM4EALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16620370 | 0.72 | HPGD (0.60) | KDM4EHTR2BALDH1A1HPGDNPC1 | |
| SCHEMBL5190191 | 0.72 | FAAH (0.59) | KDM4EALDH1A1HPGDNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3052483-B1 | COMPOUNDS FOR AFFINITY CHROMATOGRAPHY | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-02-06 | — | — | EP | disclosed |
| EP-3052483-B1 | COMPOUNDS FOR AFFINITY CHROMATOGRAPHY | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-02-06 | — | — | EP | disclosed |
| US-9938243-B2 | Compounds for affinity chromatography and for extending the half-life of a therapeutic agent | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-04-10 | — | — | US | disclosed |
| US-9938243-B2 | Compounds for affinity chromatography and for extending the half-life of a therapeutic agent | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-04-10 | — | — | US | disclosed |
| US-20170369448-A1 | COMPOUNDS FOR AFFINITY CHROMATOGRAPHY AND FOR EXTENDING THE HALF-LIFE OF A THERAPEUTIC AGENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-12-28 | — | — | US | disclosed |
| US-9809558-B2 | Compounds for affinity chromatography and for extending the half-life of a therapeutic agent | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-11-07 | — | — | US | disclosed |
| US-9809558-B2 | Compounds for affinity chromatography and for extending the half-life of a therapeutic agent | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-11-07 | — | — | US | disclosed |
| EP-3052483-A1 | COMPOUNDS FOR AFFINITY CHROMATOGRAPHY AND FOR EXTENDING THE HALF-LIFE OF A THERAPEUTIC AGENT | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2016-08-10 | — | — | EP | disclosed |
| US-20160221962-A1 | COMPOUNDS FOR AFFINITY CHROMATOGRAPHY AND FOR EXTENDING THE HALF-LIFE OF A THERAPEUTIC AGENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-08-04 | — | — | US | disclosed |
| US-20160221962-A1 | COMPOUNDS FOR AFFINITY CHROMATOGRAPHY AND FOR EXTENDING THE HALF-LIFE OF A THERAPEUTIC AGENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-08-04 | — | — | US | disclosed |
| WO-2015049651-A1 | COMPOUNDS FOR AFFINITY CHROMATOGRAPHY AND FOR EXTENDING THE HALF-LIFE OF A THERAPEUTIC AGENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-04-09 | — | — | WO | disclosed |
| WO-2015049651-A1 | COMPOUNDS FOR AFFINITY CHROMATOGRAPHY AND FOR EXTENDING THE HALF-LIFE OF A THERAPEUTIC AGENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160221962-A1 | COMPOUNDS FOR AFFINITY CHROMATOGRAPHY AND FOR EXTENDING THE HALF-LIFE OF A THERAPEUTIC AGENT | ALB, HDGF, VEGFA | ALB 1/4885KDM4E 4577/4885HTR2B 4612/4885 |
| US-20170369448-A1 | COMPOUNDS FOR AFFINITY CHROMATOGRAPHY AND FOR EXTENDING THE HALF-LIFE OF A THERAPEUTIC AGENT | ALB, HDGF, VEGFA | ALB 1/4885KDM4E 4577/4885HTR2B 4612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.